Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) is slated to report its fourth-quarter results on September 11 after the bell followed by a conference call next day. The company believes it is inching closer towards profitability as strong revenue, patient and production growth, disciplined cost management, and high-tech production could drive higher growth.
Market analysts expect the company’s high margin advantage will drive profitability and cash flows for the future. The company’s consumer market cannabis sales will continue to drive the top line fueled by additional production capacity and available supply from its Aurora Sky, MedReleaf Markham and Bradford facilities.
However, the oil and extract-based sales will continue to fall due to oil extraction capacity constraints coupled with increasing production and sale of other cannabis products. The demand for the oil and extract-based products to increase as the Canadian consumer market evolves.
On Wednesday, Aurora announced the sale of balance 28.83 million shares in The Green Organic Dutchman for aggregate gross proceeds of $86.5 million. The company’s interest in The Green Organic Dutchman became less important to its core strategy when it acquired Whistler Medical Marijuana Corp.
Analysts expect the company to report revenue of $79.02 million for the fourth quarter. This is better than the previous year quarter’s revenue of $19.15 million. Meanwhile, the company expects fourth-quarter net revenues in the range of $100 million to $107 million.
For the third quarter, the company reported a wider loss due to higher costs and expenses. Net revenue soared by 305% year-over-year due to the cannabis production capacity added by Aurora Sky and MedReleaf’s Markham and Bradford facilities. In Q3 2019, Aurora produced 15,590 kilograms of cannabis compared to 1,206 kilograms in the prior-year quarter.
For the fourth quarter, Aurora expects net cannabis revenue in the range of $90 million to $95 million. The growth is anticipated to be across all key business segments including medical, both Canadian and international, and consumer markets. Production available for sale is expected to be at the upper end of the 25,000 to 30,000 kilograms range.